Long-time biopharmaceutical executive joins Acadia board

Acadia Pharmaceuticals this week appointed Jim Daly to its board of directors.

Daly, who has three decades of experience leading national and global businesses, will use his knowledge and expertise to help the biopharmaceutical company develop and commercialize innovative medicines to treat central nervous system disorders.

Prior to joining Acadia, Daly was the EVP and chief commercial officer at Incyte Corp. where he played a significant role in advancing the launch of Jakafi. The FDA-approved drug is the first and only prescription medicine to treat individuals with polycythemia vera, a rare and chronic blood cancer, who have either had an inadequate response to or are intolerant of the medicine known as hydroxyurea.

Daly has held numerous leadership roles at biotechnology company Amgen and helped launch many products treating a variety of conditions such as anemia, osteoporosis and thrombocytopenia (low platelet count). He also served in executive positions at Glaxo Wellcome/GlaxoSmithKline, where he worked for more than 16 years and assisted in the United States launch of the asthma drug Advair.

“Jim brings extensive commercial experience to our board as we continue our transition to an integrated pharmaceutical company,” Acadia Board of Directors Chairman Leslie Iversen said. “Over the course of his career, Jim has successfully launched and commercialized major products in multiple therapeutic areas and built market-leading global franchises."